AV-1959R
Asset
Induces antibodies against amyloid-beta to promote clearance and reduce brain amyloid accumulation.
- Stage
- Phase 2
- Modality
- Vaccine
- Target
- APP
- 2
- Indications
- 1
- Trial
- 2
- Developers
Indications
2Alzheimer's disease
Phase 2, Not yet recruiting, NCT07827768, clinicaltrials.gov, 15 Oct 2026
Preclinical Alzheimer's disease
Phase 2, Not yet recruiting, NCT07827768, clinicaltrials.gov, 15 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners4
- Trials1
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.